公开(公告)号：US20200339944A1

公开(公告)日：2020-10-29

申请号：US16857394

申请日：2020-04-24

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Diego A. VARGAS-INCHAUSTEGUI ,  Thomas Charles PERTEL ,  Barbra Johnson SASU

IPC: C12N5/00 ,  C12N5/0783 ,  A61K35/17

Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).

公开(公告)号：US20240085403A1

公开(公告)日：2024-03-14

申请号：US18450554

申请日：2023-08-16

Applicant: Allogene Therapeutics, Inc.

Inventor： Thomas Charles PERTEL ,  Ren SONG ,  Diego A. VARGAS-INCHAUSTEGUI ,  Garima YAGNIK ,  Houman DEHGHANI ,  Wenjing LI ,  Jose PENA

IPC: G01N33/50 ,  C12N5/0783 ,  C12N7/00 ,  C12Q1/6851 ,  C12Q1/70

CPC classification number: G01N33/5023 ,  C12N5/0636 ,  C12N7/00 ,  C12Q1/6851 ,  C12Q1/705 ,  C12N2501/24 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2710/16521

Abstract: The instant disclosure relates to methods for preventing, controlling and/or inhibiting the rare events of adventitious viral infection or viral replication/amplification after reactivation of latent viral infection during cell culture in the manufacturing process of cell-based drug products, including CAR T cell drug products. Also provided are in vitro cell culture models for HHV-6 latent infection and methods of making the same.